Quantitation of Ubiquinone (Coenzyme Q₁₀) in Serum/Plasma Using Liquid Chromatography Electrospray Tandem Mass Spectrometry (ESI-LC-MS/MS)

Glycosaminoglycan-mediated lipoprotein uptake protects cancer cells from ferroptosis

Lipids are essential for tumours because of their structural, energetic, and signaling roles. While many cancer cells upregulate lipid synthesis, growing evidence suggests that tumours simultaneously intensify the uptake of circulating lipids carried by lipoproteins. Which mechanisms promote the uptake of extracellular lipids, and how this pool of lipids contributes to cancer progression, are poorly understood. Here, using functional genetic screens, we find that lipoprotein uptake confers resistance to lipid peroxidation and ferroptotic cell death. Lipoprotein supplementation robustly inhibits ferroptosis across numerous cancer types. Mechanistically, cancer cells take up lipoproteins through a pathway dependent on sulfated glycosaminoglycans (GAGs) linked to cell-surface proteoglycans. Tumour GAGs are a major determinant of the uptake of both low and high density lipoproteins. Impairment of glycosaminoglycan synthesis or acute degradation of surface GAGs decreases the uptake of lipoproteins, sensitizes cells to ferroptosis and reduces tumour growth in mice. We also find that human clear cell renal cell carcinomas, a distinctively lipid-rich tumour type, display elevated levels of lipoprotein-derived antioxidants and the GAG chondroitin sulfate than non-malignant human kidney. Altogether, our work identifies lipoprotein uptake as an essential anti-ferroptotic mechanism for cancer cells to overcome lipid oxidative stress in vivo, and reveals GAG biosynthesis as an unexpected mediator of this process.

Unraveling the polypharmacology of a natural antifungal product, eugenol, against Rhizoctonia solani

BACKGROUND

Rice sheath blight caused by Rhizoctonia solani is a devastating disease of rice in China. However, indiscriminate use of chemical fungicides applied to control the disease raise major environmental and food safety issues. Ecofriendly biocontrol alternatives are urgently needed. Eugenol, one of the main ingredients in Syzygium aromaticum, has attracted much attention owing to its antifungal properties. However, its mode of action is still not clear. Herein, the antifungal activity and mode of action of eugenol against R. solani were investigated.

RESULTS

Results confirmed that the mycelia of R. solani treated with eugenol shrank and became dehydrated, the cytoplasmic wall separated, and the vacuoles and mitochondria decreased or dissolved. Moreover, we found that eugenol downregulated expression of C-4 methyl sterol oxidase, inhibited synthesis of ergosterol, increased membrane permeability and impaired the transportation of amino acids and glucose across the cell membrane. In addition, eugenol decreased the mitochondrial membrane potential and initiated an oxidative stress reaction by increasing reactive oxygen species and malondialdehyde, which together with membrane damage contribute to the antifungal activity of eugenol. Meanwhile, eugenol might inhibit R. solani by affecting oxidative phosphorylation and the tricarboxylic acid cycle (TCA cycle).

CONCLUSION

In view of its multitarget properties against R. solani, eugenol provides an alternative approach to chemical control strategies against rice sheath blight. © 2021 Society of Chemical Industry.

Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy

INTRODUCTION

Multiple system atrophy (MSA) is a progressive neurodegenerative disease. Recent studies revealed decreased coenzyme Q10 (COQ10) levels in the cerebellum and blood samples of MSA patients. But few studies focused on the associations of COQ10 with the clinical symptoms of MSA. In this study, we aimed to quantify plasma COQ10 and characterize its association with clinical features.

METHODS

We recruited 40 patients with MSA, 30 patients with Parkinson's disease (PD), and 30 healthy participants. Plasma COQ10 was quantified by UPLC-MS. The basic demographic data, motor symptoms, and non-motor symptoms were also assessed.

RESULTS

Plasma COQ10 levels were significantly different in MSA, PD, and controls (P = 0.001). Post-hoc analysis revealed plasma COQ10 levels in MSA patients were lower than that in controls after adjusting for age, gender, and total cholesterol (P = 0.001). COQ10 levels differentiated MSA patients from controls with modest accuracy (P = 0.001). A sensitivity of 40% and a specificity of 97.5% was calculated with the receiver operating characteristic curve. However, COQ 10 levels did not discriminate between the MSA and PD groups (P = 0.07). Plasma COQ10 levels were correlated with the severity of motor symptoms only in MSA-C patients (b = -0.025, P = 0.009).

CONCLUSION

The association between decreased COQ10 levels and the severity of motor symptoms in MSA-C patients promotes further research. Plasma COQ10 levels alone may not be a reliable MSA diagnostic biomarker, and cannot be considered a useful biomarker in the differential diagnosis of MSA vs PD.